Search Results - PROGENSA,

The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation.

Authors: Nicholson A Mahon J Boland A et al.

Source: Health technology assessment (Winchester, England) [Health Technol Assess] 2015 Oct; Vol. 19 (87), pp. i-xxxi, 1-191.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Systematic Review

Journal Info: Publisher: NIHR Journals Library Country of Publication: England NLM ID: 9706284 Publication Model: Print Cited Medium: Internet ISSN: 2046-4924 (Electronic) Linking ISSN: 13665278 NLM ISO Abbreviation: Health Technol Assess Subsets: MEDLINE

Progensa™ PCA3 test for prostate cancer.

Authors: Durand X Moutereau S Xylinas E et al.

Source: Expert review of molecular diagnostics [Expert Rev Mol Diagn] 2011 Mar; Vol. 11 (2), pp. 137-44.

Publication Type: Journal Article

Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101120777 Publication Model: Print Cited Medium: Internet ISSN: 1744-8352 (Electronic) Linking ISSN: 14737159 NLM ISO Abbreviation: Expert Rev Mol Diagn Subsets: MEDLINE

Progensa PCA3 test for prostate cancer detection.

Authors: de la Taille A; INSERM U841Eq07, Assistance Publique des Hôpitaux de Paris, Henri Mondor Hospital, Department of Urology, CHU Mondor, 51 avenue du Maréchal de Lattre de Tassigny, 94000, Créteil, France. adelataille@hotmail.com

Source: Expert review of molecular diagnostics [Expert Rev Mol Diagn] 2007 Sep; Vol. 7 (5), pp. 491-7.

Publication Type: Journal Article; Review

Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101120777 Publication Model: Print Cited Medium: Internet ISSN: 1744-8352 (Electronic) Linking ISSN: 14737159 NLM ISO Abbreviation: Expert Rev Mol Diagn Subsets: MEDLINE

RADYOTERAPİ UYGULANAN PROSTAT KANSERLİ OLGULARDA PCA-3 SKORUNUN TEDAVİ SONU İZLEMDEKİ ROLÜ: PROSPEKTİF PİLOT ÇALIŞMA.

Authors: Bayatfard, Pantea Akçin, Oyun Portakal Hürmüz, Pervin et al.

Source: Turkish Journal of Oncology / Türk Onkoloji Dergisi. 2025 Supplement, Vol. 40, p133-133. 3/4p.

Clinical Biofluid Assays for Prostate Cancer.

Authors: Borbiev, Talaibek Kohaar, Indu Petrovics, Gyorgy

Source: Cancers. Jan2024, Vol. 16 Issue 1, p165. 14p.

Broodstock nutritional programming differentially affects the hepatic transcriptome and genome-wide DNA methylome of farmed gilthead sea bream (Sparus aurata) depending on genetic background.

Authors: Naya-Català, F. Belenguer, A. Montero, D. et al.

Source: BMC Genomics. 11/7/2023, Vol. 24 Issue 1, p1-23. 23p.

Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI.

Authors: Leyten, Gisele H. J. M. Wierenga, Elisabeth A. Sedelaar, J. P. Michiel et al.

Source: International Journal of Molecular Sciences. Jun2013, Vol. 14 Issue 6, p11347-11355. 9p. 1 Color Photograph, 1 Diagram, 2 Charts.

Source: Hologic, Inc. MarketLine Company Profile. 4/10/2026, p1-42. 42p.

Subject Terms: *Medical equipment industry

Geographic Terms: United States

Company/Entity: Hologic Inc. 153623137 HOLX

The impact of urine biomarkers for prostate cancer detection-A systematic state of the art review.

Authors: Plas S Melchior F Aigner GP et al.

Source: Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2025 Jun; Vol. 210, pp. 104699. Date of Electronic Publication: 2025 Mar 17.

Publication Type: Journal Article; Systematic Review

Journal Info: Publisher: Elsevier Scientific Publishers Country of Publication: Netherlands NLM ID: 8916049 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0461 (Electronic) Linking ISSN: 10408428 NLM ISO Abbreviation: Crit Rev Oncol Hematol Subsets: MEDLINE

Multicentre Evaluation of an AI‐Assisted Urine Test for Clinically Significant Prostate Cancer in Men Undergoing Initial Biopsy.

Authors: Jiang, Shaoqin Yang, Chunguang Huang, Zhangcheng et al.

Source: Journal of Extracellular Vesicles. Apr2026, Vol. 15 Issue 4, p1-10. 10p.

ADAMTS9‐AS2 Disrupts Docetaxel‐Resistance in Castration‐Resistant Prostate Cancer via Stemness Suppression and Ferroptosis Induction.

Authors: Liu, Ji Gao, Yan Guo, Yadong et al.

Source: Advanced Science. 2/18/2026, Vol. 13 Issue 10, p1-21. 21p.

Epigenetic and Liquid Biopsy Biomarkers in Prostate Cancer: Bridging Tumor Heterogeneity and Clinical Implementation.

Authors: Robaczyńska, Joanna Maj, Maciej Kiljańczyk, Adam et al.

Source: Cancers. Feb2026, Vol. 18 Issue 3, p389. 24p.

PCA3 as a diagnostic marker for prostate cancer: A validation study on a Swedish patient population.

Authors: Nyberg, Martin Ulmert, David Lindgren, Anna et al.

Source: Scandinavian Journal of Urology & Nephrology. Dec2010, Vol. 44 Issue 6, p378-383. 6p.

Non-Coding RNA Biomarkers in Prostate Cancer: Evidence Mapping and In Silico Characterization.

Authors: Albarracín-Navas, Lorena Lara-Salas, Nicolás I. Alarcon-Roa, Javier H. et al.

Source: Life (2075-1729). Jan2026, Vol. 16 Issue 1, p95. 18p.

Liquid biopsy for the diagnosis, prognosis, and monitoring of common cancers: global and Brazilian perspectives.

Authors: Escaleira da Silva, Milena Carvalho Campos, Viviane Souza de do Val da Silva, Manoella Paiva Areas et al.

Source: Oncologie (De Gruyter). Jan2026, Vol. 28 Issue 1, p3-32. 30p.

Effect of Divergent Genetic Selection for Growth on Spawning Quality in Gilthead Seabream (Sparus aurata).

Authors: Pérez-García, Cathaysa Lorenzo-Felipe, Álvaro Ferosekhan, Shajahan et al.

Source: Animals (2076-2615). Dec2025, Vol. 15 Issue 24, p3527. 15p.

Pathogenesis-Guided Biomarker Assessment: A Shift in Prostate Cancer Diagnostics.

Authors: Logan, Jessica M. Malone, Victoria O'Leary, John J. et al.

Source: International Journal of Molecular Sciences. Dec2025, Vol. 26 Issue 24, p11786. 12p.

The Clinical Relevance of Tumor Biomarkers in Prostate Cancer—A Review.

Authors: Majewska, Zuzanna Zajkowska, Monika Pączek, Sara et al.

Source: Cancers. Dec2025, Vol. 17 Issue 23, p3742. 17p.

Source: Hologic, Inc. MarketLine Company Profile. 10/23/2025, p1-41. 41p.

Subject Terms: *Medical equipment industry

Geographic Terms: United States

Company/Entity: Hologic Inc. 153623137 HOLX

Metamark Genetics to Serve as Exclusive Sales Agent for Hologic’s Proprietary Prostate Cancer Test

Authors: Metamark Genetics, Inc.

Source: Business Wire (English). 01/06/2016.